What Quantum-Si, Inc. told the SEC could break it.

Certain components and consumables in Quantum-Si's sequencing instruments and kits are sourced from a limited number of, or sole-source, suppliers, and losing one could interrupt its ability to make and deliver products with no assured timely alternative.

“certain of the components and consumables used in our instruments and consumable offerings are sourced from a limited number, or sole source suppliers. If we were to lose such a supplier, there can be no assurance that we will be able to identify or enter into an agreement with an alternative supplier on a timely basis on acceptable terms, if at all.”

Quantum-Si's core custom disposable semiconductor chip is assembled and packaged at a single location in Garnet Valley, Pennsylvania, so disruption there could halt production of the chip central to its sequencing platform.

“Our semiconductor chip assembly and packaging business is located in Garnet Valley, Pennsylvania.”

Quantum-Si has an accumulated deficit of $698.0 million from heavy technology investment and expects to keep devoting substantially all resources to development; though it holds $215.8M cash, it remains dependent on commercialization success and future financing.

“had an accumulated deficit of $698.0 million . These losses and accumulated deficit were primarily due to the substantial investments made to develop and improve our technology.”

Quantum-Si's products are sold for research use only, but its reagents may be used by clinical labs to create Laboratory-Developed Tests that could become subject to FDA or other regulatory requirements, adversely affecting its business.

“Our reagents may be used by clinical laboratories to create Laboratory-Developed Tests (“LDTs”), which could, in the future, become subject to some form of FDA or other regulatory requirements, which could materially and adversely affect our business and results of operations.”